摘要
目的:评价吸入布地奈德溶液治疗哮喘急性发作的有效性和安全性。方法:选择54例哮喘急性发作的中重度患者接受1周的吸入布地奈德溶液治疗,随访2周,比较用药前、用药后第24小时,48小时,停药2周时FEV1值,PEF值,FVC值及患者对疗效的自我评价。结果:治疗后各项指标均有明显改善。在肺功能改善方面优于症状改善。无明显不良反应。结论:吸入布地奈德溶液临床疗效显著,安全性好,是目前治疗哮喘急性发作的最佳的吸入激素制剂之一。
Objective： To evaluate the efficacy and safety of budesonide in the treatment of asthma stroke patients. Methods： 54 patients with moderate or severe asthma stroke were given budesonide by inhalation for 1 week and then were followed up for 2 weeks. The clinical data ,including FEV1 value, PEF value, FVC value and symptom evaluation, were compared, 24 and 48 hours before or after administration as well as at 2nd week after stopping medication. Results： The results showed every index of the patients was greatly improved after treatment,especially lung function much better than symptom improvement, without untoward side effects. Conclusion： Budesonide is one of the ,hOSt effective and safest inhaled corticosteroids in the treatment of the patients with asthma stroke at present.
出处
《现代生物医学进展》
CAS
2006年第11期152-152,共1页
Progress in Modern Biomedicine
